You are here

EREKTİL DİSFONKSİYONDA ENDOKRİN SEBEPLERİN GÖRÜLME SIKLIĞI

Journal Name:

Publication Year:

Keywords (Original Language):

Abstract (2. Language): 
Little is known about the natural history of erectile dysfunction. Erectile dysfunction is clearly a symptom of many conditions and certain risk factors have been identified, some of which may be emanable to prevention strategies. Among these, hypogonadism in association with a number of endocrinologic conditions have been demonstrated as a risk factor. Design.- Over a period of 7 years, from 1991 to 1998, 2750 men who had referred to our sexual dysfunctions center for erectile dysfunction have been evaluated. Sexual hystory, physical examination, hormonal evaluation (prolactin, free testosterone), Doppler ultrasound, intracavernous pharmacotest and if indicated DICC and neurologic evaluation have been performed. Data were analyzed from the files of the patients. Patients with endocrinological causes without other etiology were included in the study group. The mean age of the patients were 39.2 (range 23-75). The therapy given and results of the therapy were analyzed. Results.- Sexual history revealed 69/2750 (2.5 %) of the patients had primary impotence. 1100 (40.5%) patients were diabetic. Although diabetus mellitus is the most common endocrinologic cause of impotence, endocrine causes were detected in 190 patients (7%). In diabetic patients not only one factor could be determined as a cause of impotence. Cardiovascular disease was appearent in 495 patients (17.6%). Hormonal evaluation showed hyperprolactinemia in 19 of 190 (10%) patiens, hyperprolactinemia + androgen deficiency in 97 (50.8%), androgen deficiency in 74 (39.2%) patients. After the testosterone replacement therapy, 49 (70%) of the patients reported increase in penile rigidity and seminal volume and were satisfied with the therapy while 21 (30%) of the patients needed self-injection pharmacotherapy. In patients with hyperprolactinemia, bromocriptine is used and only 16% of satisfactory results were obtained. Overall success rate was 37% with hormonal therapy. Conclusions.- Impotence is a major health concern. There are many determinants related to the risk factors and not only one factor could be determined as the etiological factor for erectile dysfunction. In patients with an etiology of endocrine causes, hormonal therapy is advisable but further other therapies may also be needed in case of unsatisfaction.
Abstract (Original Language): 
Erektil disfonksiyon etyolojisinde bir çok faktörün yer aldığı bir patolojidir. Bu nedenlerin belirlenmesi tedavi stratejimizi de belirleyecektir. Hastaların bir bölümünde endokrin kaynaklı sebepler erektil disfonksiyonun sebebi olabilmektedir. 1991-1998 yılları arasında erektil disfonksiyon şikayeti ile cinsel disfonksiyon merkezimize başvuran 2750 erkek hastanın kayıtları retrospektif olarak değerlendirildi. Anamnez, fizik muayene, hormonal tetkik (prolaktin, serbest testosteron), penil Doppler USG, intrakavernöz farmakotest, kavernozometre ve nörolojik muayeneleri incelendi. Yalnızca endokrinolojik sebeplere bağlı erektil disfonksiyonu olan hastalar çalışma grubuna dahil edildi. Verilen tedavinin sonuçları analiz edildi. Anamnez ile %2,5 (69/2750) hastada primer erektil disfonsiyon saptandı. Hastaların ortalama yaşı 39,2 (23-75) olarak tespit edildi. 1100 (%40,5) hasta diabetikdi. 190 hastada (%7) endokrin nedenler etyolojide saptandı. Hormonal değerlendirme sonucu 190 hastanın 19'unda (%10) hiperprolaktinemi, 97 hastada (%50,8) hiperprolaktinemi + androgen eksikliği, 74 hastada ise (%39,2) yalnızca androgen eksikliği saptandı. Testosteron replasman tedavisi sonrası 49 hastada (%70) klinik düzelme (penil rijiditede ve seminal miktarda artış) sağlanırken 21 hastada (%30) klinik düzelme sağlanamadı ve enjeksiyon tedavisine ihtiyaç duyuldu. Hiperprolaktinemi nedeniyle bromokriptin tedavisi alan hastaların %16'sında klinik düzelme sağlandı. Toplam olarak hormonal tedavinin başarı oranı %37 olarak belirlendi. Erektil disfonksiyon önemli bir sağlık problemidir. Etyolojide birçok risk faktörü bulunmaktadır. Endokrin sebeplerin etyolojide yer aldığı hastalarda hormonal tedavi ile bir kısım hastada sonuç alınabilmektedir, ancak başarısız olunan vakalarda diğer tedavi seçeneklerine ihtiyaç duyulabilir.
265-268

REFERENCES

References: 

1. Zonzstein J. Diagnosis and management of endocrine disorders of erectile dysfunction. Urol Clin N Amer 1995; 22: 789.
2. Buvat J, Lemaire A, Buvat-Herbaut M, Fourlinnie J, Racadot A, Fossati P. Hyperprolactinemia and sexual function in men. Hormone Res 1985; 22: 196.
3. Johnson A, Jarrow J. Is routine endocrine testing of impotent men necessary? J Urol 1992; 147: 1542.
4. Kropman R, Verdijk R, Lycklama A, Nijeholt A, Roelfsema F. Routine endocrine screening in impotence: Significance and cost efectiveness. Int J Impotence Res 1991; 3: 87.
5. Keogh E, Caratic C, Earle C, Wisnievski ZS. Diagnosis and medical treatment of erectile dysfunction. Elsevier Science 1986; 406-415.
6. Spark RF, White RA, Connolly PM. Impotance is not always psychogenic. JAMA 1980; 243: 750.
7. Buvat J, Lemaire A. Endokrine screening in 1022 men with erectile dysfunction: Clinical significance and cost-effective strategy. J Urol 1997; 158: 1764-1767.
8. Morales A, Johnstone B, Heaton JV, Clark A. Oral androgens in the treatment of hypogonadal impotent men. J Urol 1994;152: 1115.
9. NIH consensus conference: Impotence. JAMA 1993; 270: 83-87.

Thank you for copying data from http://www.arastirmax.com